109186 ⎘
Structure or type of the nucleic acid; Chemical structure; Spatial arrangement of the modifications Gapmers, i.e. of the type ===---===
Modified RNAi polynucleotides and uses thereof
#902Modulation of apolipoprotein (a) expression
#903TRPM-2 antisense therapy
#904RNAi probes targeting cancer-related proteins
#905Antisense oligonucleotides targeted to the coding region of thymidylate synthase and uses thereof
#906Peptide-conjugated oligonucleotide therapeutic and method of making and using same
#907Antidotes to antisense compounds
#908EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS
#909METHODS AND COMPOSITONS FOR ANTISENSE VEGF OLIGONUCLEOTIDES
#910Modulation of SGLT2 expression
#911Lipid formulation
#912RNA Antagonist Compounds for the Modulation of MCL-1
#913MODULATION OF HIF1 BETA EXPRESSION
#914Modulation of forkhead box O1A expression
#915Modulation of stat5 expression
#916Modulation of factor 7 expression
#917Administering antisense oligonucleotides complementary to human apolipoprotein B
#918Antisense modulation of fibroblast growth factor receptor 4 expression
#919Modulation of apolipoprotein (A) expression
#920Method for inhibiting the activity of mir-155
#921SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HIF-1ALPHA
#922Oligomeric compounds and compositions for use in modulation of pri-miRNAs
#923Antisense modulation of kinesin-like 1 expression
#924LNA antagonists targeting the androgen receptor
#925MODULATION OF GLUCAGON RECEPTOR EXPRESSION
#926MODULATION OF GLUCOCORTICOID RECEPTOR EXPRESSION
#927Short oligomer antagonist compounds for the modulation of target mRNA
#928Modulation of Stat 6 Expression for the Treatment of Airway Hyperresponsiveness
#929ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EXPRESSION
#930Antisense compounds
#9315'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
#932MODULATION OF SID-1 EXPRESSION
#933OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA
#934Methods for treating hypercholesterolemia
#935Modulation of factor 11 expression
#936Pure miRNA Sample Preparation Method
#937Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
#938MODULATION OF eIF4E EXPRESSION
#939Methods for treating multiple sclerosis using antisense oligonucleotides
#940Modulation of HIF1-beta expression
#941Oligomeric compounds for the modulation of HIF-1alpha expression
#942METHODS FOR SLOWING FAMILIAL ALS DISEASE PROGRESSION
#943COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#944Combination therapy using budesonide and antisense oligonucleotide targeted to IL4-receptor alpha
#945MODULATION OF TOLL-LIKE RECEPTOR 8 EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES
#946EFFICIENT REDUCTION OF TARGET RNA'S BY SINGLE- AND DOUBLE-STRANDED OLIGOMERIC COMPOUNDS
#947Antisense modulation of connective tissue growth factor expression
#948Compositions and their uses directed to PTPR alpha
#949Long interfering nucleic acid duplexes targeting multiple RNA targets
#950COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF CRP
#951COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF SGLT2
#952ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
#953Compounds and methods for modulating expression of PTP1B
#954Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#955Compositions and their uses directed to IL-4R alpha
#956Compounds and methods for modulating expression of GCCR
#957Compounds and methods for modulating expression ApoB
#958Compounds and methods for modulating expression of GCGR
#959CONJUGATED DOUBLE STRAND COMPOSITIONS FOR USE IN GENE MODULATION
#960Compounds and methods for modulating expression of PCSK9
#961Regulation of epigenetic control of gene expression
#962Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#963MODULATION OF STAT 6 EXPRESSION
#964COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF DGAT2
#965Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#966Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#967Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs
#968Potent LNA oligonucleotides for the inhibition of HIF-1a expression
#969Compositions and Their Uses Directed to IL-4R Alpha
#970Antisense modulation of C-reactive protein expression
#971MODULATION OF TUDOR-SN EXPRESSION
#972HUMAN RNASE III AND COMPOSITIONS AND USES THEREOF
#973DELIVERY OF POLYNUCLEOTIDE AGENTS TO THE CENTRAL NERVOUS SYSTEM
#974Modulation of the Transcription of Pro-Inflammatory Gene Products
#975Oligomeric compounds and compositions for the use in modulation of microRNAs
#976MODULATION OF LMW-PTPASE EXPRESSION
#977Oligonucleotides with alternating segments of locked and non-locked nucleotides
#978MODULATION OF CHREBP EXPRESSION
#979Modulation of eIF4E-BP2 expression
#980MIR-150 FOR THE TREATMENT OF BLOOD DISORDERS
#981RNA antagonist compounds for the modulation of PIK3CA expression
#982Modulation of eIF4E expression
#983MODULATION OF STAT 6 EXPRESSION FOR THE TREATMENT OF AIRWAY HYPERRESPONSIVENESS
#984LNA antagonists targeting the androgen receptor
#985Modulation of C-reactive protein expression
#986MODULATION OF ENDOTHELIAL LIPASE EXPRESSION
#987Antisense modulation of PTP1B expression
#988RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION
#989Modulation of diacylglycerol acyltransferase 1 expression
#990Modulating Gene Expression with agRNA and Gapmers Targeting Antisense Transcripts
#991Modulation of eIF4E-BP2 expression
#992Modulation of transthyretin expression
#993Modulation of apolipoprotein (a) expression
#994Inhibitors of prolyl-hydroxylase-1 for the treatment of skeletal muscle degeneration
#995Topical administrations of antisense compounds to VLA-4 for the treatment of respiratory conditions
#996Antisense oligonucleotides against thymidylate synthase
#997Isis Pharmaceuticals, Inc.
#998Pharmaceutical Composition Containing Meltrin Antagonist
#999Compositions and their uses directed to PTPRU
#1000RNAi probes targeting cancer-related proteins
#1001Suppression of nuclear factor-κB dependent processes using oligonucleotides
#1002Chimeric Gapped Oligomeric Compounds
#1003Compositions and methods for the modulation of JNK proteins
#1004Antisense modulation of apolipoprotein B expression
#1005Materials and methods for treatment of cancer
#1006Method For Preventing or Treating Pain in a Mammal
#1007Methods for the Delivery of Oligomeric Compounds
#1008Antisense modulation of p38 mitogen activated protein kinase expression
#1009Oligomeric compounds for the modulation ras expression
#1010ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EXPRESSION
#1011Modulation of FR-alpha expression
#1012Modulation of forkhead box O1A expression
#1013Antisense modulation of stearoyl-CoA desaturase expression
#1014Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
#1015Clusterin antisense therapy for treatment of cancer
#1016COMPOSITIONS AND THEIR USES DIRECTED TO IL-4R ALPHA
#1017Suppression of nuclear factor-κB dependent processes using oligonucleotides
#1018TRPM-2 antisense therapy
#1019ANTISENSE OLIGONUCLEOTIDE MODULATION OF STAT3 EXPRESSION
#1020Compositions and their uses directed to huntingtin
#1021Short antisense compounds with gapmer configuration
#1022Antisense modulation of kinesin-like 1 expression
#1023BACKBONE MODIFICATIONS TO MODULATE OLIGONUCLEOTIDE TARGETING IN VIVO
#1024COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#1025Modulation of STAT5 expression
#1026Compositions and their uses directed to hepcidin
#1027THERAPEUTIC DRUG COMBINATIONS AND DELIVERY SYSTEMS COMPRISING C-RAF KINASE ANTISENSE POLYNUCLEOTIDES FOR TREATING OCULAR DISEASES AND DISORDERS
#1028Modulation of telomere length by oligonucleotides having a G-core sequence
#1029MODULATION OF THYROID HORMONE RECEPTOR INTERACTOR 3 EXPRESSION
#1030Modulation of glucagon receptor expression
#1031MODULATION OF GLUCAGON RECEPTOR EXPRESSION
#1032MODULATION OF GLUCAGON RECEPTOR EXPRESSION
#1033MODULATION OF GLUCAGON RECEPTOR EXPRESSION
#1034MODULATION OF ACE2 EXPRESSION
#1035Data correction apparatus, data correction method, magnetic resonance imaging apparatus and X-ray CT apparatus
#1036DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#1037DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#1038Modulation of ace2 expression
#1039DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#1040DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#1041DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#1042DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#1043Antisense IAP nucleobase oligomers and uses thereof
#1044DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#1045DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#1046DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#1047DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#1048DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#1049DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#1050DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#1051COMPOSITIONS AND THEIR USES DIRECTED TO IL-4R ALPHA
#1052Compositions and their uses directed to IL-4R alpha
#1053Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
#1054Antisense IAP oligonucleotides and uses thereof
#1055Antisense IAP nucleobase oligomers and uses thereof
#1056DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#1057Antisense IAP oligonucleotides and uses thereof
#1058Methods for slowing familial ALS disease progression
#1059Modulation of glucagon receptor expression
#1060Modulation of glucocorticoid receptor expression
#1061Modulation of eIF4E expression
#1062Pure miRNA Sample Preparation Method
#1063Antisense modulation of superoxide dismutase 1, soluble expression
#1064Methods for use in modulating miR-122a
#1065Antisense modulation of fibroblast growth factor receptor 3 expression
#1066Antisense IAP nucleobase oligomers and uses thereof
#1067Antisense IAP nucleobase oligomers and uses thereof
#1068Modulation of SOCS-3 expression
#1069Modulation of HIF1alpha and HIF2alpha expression
#1070Modulation of endothelial lipase expression
#1071Antiviral oligonucleotides having a conserved G4 core sequence
#1072Antisense modulation of superoxide dismutase 1, soluble expression
#1073Modulation of apolipoprotein (A) expression
#1074Modulation of apolipoprotein c-III expression
#1075Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
#1076Combined therapy utilizing reduction of DNA methyltransferase expression and/or activity and interferon
#1077Oligomeric compounds and compositions for use in modulation of pri-mirnas
#1078Potent LNA oligonucleotides for the inhibition of HIF-1A expression
#1079Modulation of HIF-1 beta expression
#1080Compositions and their uses directed to thymus and activation-regulated chemokine (TARC)
#1081Antisense oligonucleotide modulation of STAT3 expression
#1082Delivery of polynucleotide agents to the central nervous system
#1083Antisense modulation of farnesoid X receptor expression
#1084RNAi probes targeting cancer-related proteins
#1085Modification of MyD88 splicing using modified oligonucleotides
#1086Antisense modulation of integrin beta 4 binding protein expression
#1087Oligonucleotide inhibitors of MBD2/DNA demethylase and uses thereof
#1088Modulation of glucocorticoid receptor expression
#1089Antisense modulation of CD40 ligand expression
#1090Modulation of SLC26A2 expression
#1091Antisense oligonucleotide modulation of raf gene expression
#1092Amino-LNA, thio-LNA and alpha-L-oxy-LN
#1093Use of mob-5 in pain
#1094Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression
#1095Antisense oligonucleotides for identifying drug targets and enhancing cancer therapies
#1096Conjugates for use in hepatocyte free uptake assays
#1097Antisense modulation of matrix metalloproteinase 1 expression
#1098Oligomeric compounds effecting drosha-mediated cleavage
#1099Enhanced antisense oligonucleotides
#1100Antisense modulation of hematopoietic cell protein tyrosine kinase expression
#1101Antisense oligonucleotides directed to genes regulated by trapoxin-induced HDAC inhibition
#1102Methods for modulating lipoprotein and cholesterol levels in humans
#1103Antisense modulation of c/ebp beta expression
#1104Modulation of glucocorticoid receptor expression
#1105Antisense modulation of PTP1B expression
#1106Antisense modulation of C-reactive protein expression
#1107Effects of apolipoprotein B inhibition on gene expression profiles in animals
#1108Bispecific oligonucleotide for the treatment of CNS malignancies
#1109Oligomeric compounds having modified phosphate groups
#1110SNPs of apolipoprotein B and modulation of their expression
#1111Modulation of growth hormone receptor expression and insulin-like growth factor expression
#1112Antisense modulation of ptpn12 expression
#1113Modulation of Aurora B expression
#1114Antisense modulation of p70 S6 kinase expression
#1115Modulation of glucose-6-phosphatase translocase expression
#1116Antisense modulation of interleukin 12 P35 subunit expression
#1117Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1118Modulation of pumilio 1 expression
#1119Modulation of Nanos 1 expression
#1120Antisense modulation of cellular apoptosis susceptibity gene expression
#1121Double stranded constructs comprising one or more short strands hybridized to a longer strand
#1122Modulation of transthyretin expression
#1123Modulation of STAT 6 expression
#1124Modulation of kallikrein 6 expression
#1125Antisense modulation of TFAP2C expression
#1126Antisense modulation of thyroid hormone receptor interactor 6 expression
#1127Vascular therapeutics
#1128Antisense modulation of mucin 1, transmembrane expression
#1129Hepatocyte free uptake assays
#1130Modulation of tyrosinase expression
#1131Antisense modulation of sterol regulatory element-binding protein-1 expression
#1132Compositions and their uses directed to signal transducers
#1133Antisense modulation of cellular inhibitor of Apoptosis-2 expression
#1134Antisense modulation of dual specific phosphatase 5 expression
#1135Modulation of eIF4E-BP2 expression
#1136Modulation of SGLT2 expression
#1137Compositions and their uses directed to cell growth and maintenance proteins
#1138Antisense modulation of peroxisome proliferator-activated receptor gamma expression
#1139Antisense modulation of EIF2C1 expression
#1140Modulation of DC-SIGN expression
#1141Modulation of eIF4E-BP1 expression
#1142Antisense modulation of microsomal triglyceride transfer protein expression
#1143Chemically modified double stranded nucleic acid molecules
#1144Compositions and their uses directed to binding proteins
#1145Modulation of glucocorticoid receptor expression
#1146Compositions and their uses directed to metabolic proteins
#1147Methods of using mammalian RNase H and compositions thereof
#1148Hepatocyte free uptake assays
#1149Human RNase III and compositions and uses thereof
#1150Compositions and their uses directed to transferases
#1151Antisense modulation of interferon gamma receptor 2
#1152Antisense modulation of extracellular-signal-regulated kinase-6 expression
#1153Compositions and their uses directed to nucleic acid binding proteins
#1154Antisense modulation of survivin expression
#1155Antisense modulation of phospholipase A2, group IIA (synovial) expression
#1156Microrna as ligands and target molecules
#1157Antisense modulation of cholesteryl ester transfer protein expression
#1158Compositions and their uses directed to signal tranducers
#1159Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
#1160Vascular therapeutics
#1161Antisense oligonucleotides optimized for kidney targeting
#1162Antisense modulation of inducible nitric oxide synthase expression
#1163Antisense modulation of polo-like kinase expression
#1164Modulation of CEACAM1 expression
#1165Antisense modulation of PLML expression
#1166Antisense modulation of caspase 7 expression
#1167Antisense modulation of calreticulin expression
#1168Modulation of STAT5 expression
#1169Modulation of phosphodiesterase 4B expression
#1170Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
#1171Notch1 inhibitors for inducing apoptosis
#1172Antisense modulation of PTP1B expression
#1173Modulation of aminopeptidase N expression
#1174Antisense modulation of wrn espression
#1175Antisense oligonucleotide modulation of STAT3 expression
#1176Antisense modulation of ptpn2 expression
#1177Antisense modulation of acyl coenzyme a cholesterol acyltransferase-1 expression
#1178Mouse model for bone metabolism
#1179Antisense modulation of connective tissue growth factor expression
#1180Structural motifs and oligomeric compounds and their use in gene modulation
#1181Modified protein kinase a-specific oligonucleotides and methods of their use
#1182Antisense oligonucleotide modulation of tumor necrosis factor-alpha (TNF-alpha) expression
#1183Antisense modulation of insulin-like growth factor binding protein 5 expression
#1184Antisense modulation of stearoyl-CoA desaturase expression
#1185Phosphorous-linked oligomeric compounds and their use in gene modulation
#1186Modulation of the RNA interference pathway
#1187Non-phosphorous-linked oligomeric compounds and their use in gene modulation
#1188Antisense modulation of breast cancer-1 expression
#1189Antisense modulation of superoxide dismutase 1, soluble expression
#1190Modulation of glucagon receptor expression
#1191Modulation of C-reactive protein expression
#1192Antisense modulation of hypothetical protein LOC51249 expression
#1193Antisense modulation of apolipoprotein B-expression
#1194Conjugated antisense compounds and their use
#1195Compounds and methods for reducing LRRK2 expression
#1196Chimeric oligomeric compounds and their use in gene modulation